DengiAll Dengue Vaccine in Phase III Trial
1 June 2026National
Panacea Biotec, overseen by ICMR, advanced Phase III clinical trials of its indigenous dengue vaccine candidate DengiAll, enrolling over 10,000 volunteers across India.
More International Current Affairs
IIT Madras and UNESCO MGIEP Partner to Develop AI-Based Immersive Learning Tools
GK Byte
📅 6 Sept 2026InternationalRead complete →
NIELIT and Intel India Launch Agentic AI Skilling Programmes at National Leadership Dialogue
GK Byte
📅 5 Sept 2026InternationalRead complete →
Tata Elxsi and Sarla Aviation Partner to Develop the 'Shunya' Electric Air Taxi
GK Byte
📅 3 Sept 2026InternationalRead complete →
IISc Sets Up Foundation for Quantum Computing Innovation as the National Quantum Mission's Computing Hub
GK Byte
📅 2 Sept 2026InternationalRead complete →